Connect Biopharma celebrates a mid-stage win for its Dupixent rival, but shares tank after investors clamor for data

A suite of drugmakers is looking to topple Dupixent in the eczema market — and on Thursday, China-based Connect Biopharma uncorked some mid-stage results it says will pave the way to a pivotal trial. But investors want hard numbers, and without any to share, the company’s stock

Click to view original post